News und Analysen
![Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News: https://g.foolcdn.com/editorial/images/733269/two-investors-consider-a-stock-with-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODRWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3919acfafdf96a1e2d029db4acfd8149c569fddb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-investors-consider-a-stock-with-laptop.jpg?locale=de)
Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News
On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43
![2 Bear Market Defying Stocks to Buy in May: https://g.foolcdn.com/editorial/images/733053/doctor-smiling-and-holding-patients-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXNWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e73ea7828d149d53d9841ec5869a09068c1b9e40/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-smiling-and-holding-patients-hand.jpg?locale=de)
2 Bear Market Defying Stocks to Buy in May
Equities experienced a bear market in 2022, and although things have improved significantly over the past few months, it's impossible to say whether we are out of the woods. However, some
![Here's Why This Little-Known Growth Stock Is a Buy: https://g.foolcdn.com/editorial/images/733060/a-person-speaks-to-their-doctor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMTRWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--90ca19cb22ba1c4e12a1d55453c81739c12d0655/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-speaks-to-their-doctor.jpg?locale=de)
Here's Why This Little-Known Growth Stock Is a Buy
Buying growth stocks on the cheap can be a great way to build wealth for investors with enough patience. This is because the strategy combines the high return potential of growth investing with the
![2 Hot Stocks to Buy and Hold Until You Retire: https://g.foolcdn.com/editorial/images/732992/a-group-of-people-laughing.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMkFWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--309c8f58166dc0abdda1d19b17bc334f5513811f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-group-of-people-laughing.jpg?locale=de)
2 Hot Stocks to Buy and Hold Until You Retire
Long-term investors recognize the benefits of a buy-and-hold strategy. The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds. While 2022 was
![Should Income Investors Buy This Big Pharma Stock?: https://g.foolcdn.com/editorial/images/733096/healthcare-professionals-talking-to-each-other.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2dVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--29f266cb6a6d81896621b5066f5138d572ade0cd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-professionals-talking-to-each-other.jpg?locale=de)
Should Income Investors Buy This Big Pharma Stock?
Amid the start of the COVID-19 pandemic, big pharma companies like Pfizer (NYSE: PFE) began expedited clinical trials of COVID-19 vaccines and antiviral treatments. And a combination of incredible
![Trupanion's Sales Are Surging on Puppy Love That Should Have Growth Investors Salivate: https://g.foolcdn.com/editorial/images/732763/a-veterinarian-examines-a-cat.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGtVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0f3f5565beb006a87360a14df23adde107d6a0a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-veterinarian-examines-a-cat.jpg?locale=de)
Trupanion's Sales Are Surging on Puppy Love That Should Have Growth Investors Salivate
Anyone who has followed the stock market for years will attest the market isn't always rational in the near term. At the drop of a hat, a stock can receive more praise and price appreciation than it
![3 Relatively Safe Stocks to Buy if a Recession Is on the Way: https://g.foolcdn.com/editorial/images/733041/person-looking-at-laptop-with-hand-to-face.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzhVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e28d7df335ecb0a261e91e6b396e454a8beaaf7a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-looking-at-laptop-with-hand-to-face.jpg?locale=de)
3 Relatively Safe Stocks to Buy if a Recession Is on the Way
We don't have a modern-day Paul Revere riding a horse through the streets shouting that a recession is coming. But we don't need one, as there are plenty of economists, analysts, and even the
![Why CymaBay Therapeutics Stock Nose-Dived This Week: https://g.foolcdn.com/editorial/images/733290/medical-professionals-conferring-in-a-hospial-corridor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVlVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dae887395d1a4197a230e04331916c5b8816cf62/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medical-professionals-conferring-in-a-hospial-corridor.jpg?locale=de)
Why CymaBay Therapeutics Stock Nose-Dived This Week
A significant miss on quarterly earnings combined with a big change in its C-suite put a damper on CymaBay Therapeutics (NASDAQ: CBAY) stock this week. According to data compiled by S&P Global
![Why Shares of Nutex Health Jumped on Friday: https://g.foolcdn.com/editorial/images/733251/doctors-white-coat-healthcare-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekFVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d86a1d83823fd393234c83625bd2706b96539404/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctors-white-coat-healthcare-1.jpg?locale=de)
Why Shares of Nutex Health Jumped on Friday
Shares of Nutex Health (NASDAQ: NUTX) were up more than 12% Friday afternoon after being up as much as 24% earlier in the day. The company provides technology-driven healthcare management and
![Why Shares of Catalent Were Up Friday: https://g.foolcdn.com/editorial/images/733218/pharmaceutical-factory-worker.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeU1VYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d6dcb40199febf0fa7dacca1304d9017cfa3f25c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pharmaceutical-factory-worker.jpg?locale=de)
Why Shares of Catalent Were Up Friday
Shares of contract drug manufacturer Catalent (NYSE: CTLT) were up more than 14% Friday afternoon after the healthcare company announced updated guidance and said it was delaying its third-quarter
![1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market: https://g.foolcdn.com/editorial/images/732403/a-team-of-scientists-reviewing-results-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOElUYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0f6ee01c21638ce8bbe3e90891d0411b83f0fc2f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-team-of-scientists-reviewing-results-in-a-lab.jpg?locale=de)
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months
![3 Safe Dividend Stocks to Beat Inflation: https://g.foolcdn.com/editorial/images/732888/dividend-income.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMThUYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d55b09b68a04438c44e7dbb7d707d09a9d4981d4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dividend-income.jpg?locale=de)
3 Safe Dividend Stocks to Beat Inflation
Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and
![Why Viking Therapeutics Stock Is Buckling Today: https://g.foolcdn.com/editorial/images/733067/downward-trend.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1lTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4b5499fc1b37357c6bd3aee35fb4dc812f5f204c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/downward-trend.jpg?locale=de)
Why Viking Therapeutics Stock Is Buckling Today
Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics (NASDAQ: VKTX) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares are
![Thinking of Buying Novavax Stock? 3 Numbers You Should Look at First: https://g.foolcdn.com/editorial/images/732412/people-working-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3dTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a09c6bfbc3c1e4dae673a8b9647fa1b73059fa83/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/people-working-in-a-lab.jpg?locale=de)
Thinking of Buying Novavax Stock? 3 Numbers You Should Look at First
There's been lots of excitement surrounding Novavax (NASDAQ: NVAX). The company beat earnings expectations for the first quarter as it has been slashing expenses, and recent clinical trials --
![Is This Healthcare Stock a Buy for Dividend Growth Investors?: https://g.foolcdn.com/editorial/images/732621/a-doctor-consults-with-their-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzhRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a500ec78676d4a942d9687e806074a065f2872de/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-doctor-consults-with-their-patient.jpg?locale=de)
Is This Healthcare Stock a Buy for Dividend Growth Investors?
Provided that your portfolio is diversified to properly hedge against the risks associated with investing in stocks, it merely takes time, patience, and some well-thought-out picks to grow richer.
![Is a Victory for Its Rivals Bad News for Axsome Therapeutics?: https://g.foolcdn.com/editorial/images/732518/gettyimages-woman-writes-on-clipboard.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeElRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dd703f397d982b74edfb8d73524c92cb6ece2ce7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-woman-writes-on-clipboard.jpg?locale=de)
Is a Victory for Its Rivals Bad News for Axsome Therapeutics?
Axsome Therapeutics (NASDAQ: AXSM) wowed investors late last year with strong data from a phase 3 study of AXS-05, its candidate treatment for Alzheimer's disease agitation. AXS-05 met its primary
![FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?: https://g.foolcdn.com/editorial/images/732729/handshake-broken.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG9RYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2598da62d287123b33e549c213e3e2db8ca363a2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/handshake-broken.jpg?locale=de)
FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?
Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).
The Federal Trade Commission
![Is This Dow Jones Stock a Buy for Income Investors?: https://g.foolcdn.com/editorial/images/732584/a-doctor-examines-a-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeDhRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0a1a84ae5c4d8cc2204b72cbca51f62a5023f7d1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-doctor-examines-a-patient.jpg?locale=de)
Is This Dow Jones Stock a Buy for Income Investors?
Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest
![The FTC Wants to Block the $28 Billion Amgen-Horizon Therapeutics Deal: https://g.foolcdn.com/editorial/images/732811/featured-daily-upside-image.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOVlQYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--88816a865e2682746d2d0bdb4c384e91b18759d2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-daily-upside-image.jpg?locale=de)
The FTC Wants to Block the $28 Billion Amgen-Horizon Therapeutics Deal
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.
Big Pharma needs
![Why Viking Therapeutics Stock Bolted Higher Today: https://g.foolcdn.com/editorial/images/732774/parabola.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1FQYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--76729b19924b6845a765803ad3afbe1ef156ad07/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/parabola.jpg?locale=de)
Why Viking Therapeutics Stock Bolted Higher Today
Shares of clinical-stage metabolism specialist Viking Therapeutics (NASDAQ: VKTX) were up by 12.4%, on abnormally high volume, as of 3:12 p.m. ET Tuesday afternoon. The big gain came after the
![Why These 3 Nasdaq Stocks Buckled Today: https://g.foolcdn.com/editorial/images/732725/downward-trend.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1VQYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6938b7b19b7620d46e08f1cac8eb702bd4307404/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/downward-trend.jpg?locale=de)
Why These 3 Nasdaq Stocks Buckled Today
Biotech stocks have been on a wild ride this year. For instance, the bellwhether SPDR S&P Biotech ETF (NYSEMKT: XBI) has been up by as much as 9%, and down by as much as 12%, during just the first
![Why Shares of Savara Jumped on Tuesday: https://g.foolcdn.com/editorial/images/732720/healthcare-lab-treatment-research-scientist-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMUVQYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b0fba863bdd61a2e0d55bb8ea74b64a9c8828e02/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-lab-treatment-research-scientist-1.jpg?locale=de)
Why Shares of Savara Jumped on Tuesday
Shares of Savara (NASDAQ: SVRA) rose more than 9% Tuesday morning after the company released first-quarter earnings. The stock is up more than 38% so far this year. Savara is a a clinical-stage phar
![Which Is the Better Forever Stock: Johnson & Johnson or UnitedHealth Group?: https://g.foolcdn.com/editorial/images/732093/adaptimmune.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd01QYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2bfcda918120942cfe866c4641b95e9987f4f769/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/adaptimmune.jpg?locale=de)
Which Is the Better Forever Stock: Johnson & Johnson or UnitedHealth Group?
Johnson & Johnson (NYSE: JNJ) and UnitedHealth Group (NYSE: UNH) are considered great healthcare stocks to hold for the long term because of their size, steady cash flow, and above-average
![3 Exceptional Dividend Stocks That Retirees Should Love: https://g.foolcdn.com/editorial/images/732415/investing-screen-analysis-investor-growth-stocks-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWdPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--66a40bf902469595a7628457ef2b234fe1de0057/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investing-screen-analysis-investor-growth-stocks-getty.jpg?locale=de)
3 Exceptional Dividend Stocks That Retirees Should Love
Investors looking to secure a steadily growing passive income stream have all sorts of options, but few are easier to implement than buying dividend-paying stocks. That said, not every dividend
![CorMedix (CRMD) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
CorMedix (CRMD) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
CorMedix (NASDAQ: CRMD)Q1 2023 Earnings CallMay 15, 2023, 4:30 p.m. ET
Operator
Source Fool.com